COST-EFFECTIVENESS ANALYSIS OF ADJUVANTALECTINIB COMPARED TO PLATINUM-BASED ADJUVANTCHEMOTHERAPY IN PATIENTS WITH RESECTABLE ALK-POSITIVE NSCLC IN ITALY

被引：0
|
作者：
Paoletti, M. [1 ]
Scansetti, V [1 ]
Cazzato, D. [1 ]
Marcellusi, A. [2 ]
Belfiore, M. [3 ]
Isoko, J. [4 ]
Pacifici, M. [4 ]
Cortinovis, L. D. [5 ]
Veronesi, G. [6 ]
机构：
[1] Univ Roma Tor Vergata, Fac Econ, Dept Econ & Finance, Econ Evaluat & HTA EEHTA CEIS, Rome, RM, Italy
[2] Univ Milan, Milan, Italy
[3] Roche Spa, Milan, MI, Italy
[4] Roche Spa, Milan, MI, Italy
[5] Univ Milano Bicocca, Dept Med, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE459
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China
    Zhang, Meiling
    Zheng, Bei
    Yang, Wenjuan
    Jiang, Hong
    Sun, Xueshan
    Zhao, Zixuan
    Li, Gonghua
    Dong, Hengjin
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
  • [2] Cost-Effectiveness Analysis of Adjuvant Alectinib versus Platinum-Based Chemotherapy in Resected ALK-Positive Non-Small-Cell Lung Cancer in the Chinese Health Care System
    Wei, Qiran
    Liang, Yifang
    Mao, Jiahui
    Guan, Xin
    CANCER MEDICINE, 2024, 13 (22):
  • [3] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ALECTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN RESECTED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER IN THE CHINESE HEALTH CARE SYSTEM
    Wei, Q.
    Mao, J.
    Liang, Y.
    Guan, X.
    VALUE IN HEALTH, 2024, 27 (12) : S86 - S87
  • [4] Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Gadgeel, S.
    Dziubek, K.
    Nagasaka, M.
    Braun, T.
    Hassan, K.
    Cheng, H.
    Wozniak, A.
    Halmos, B.
    Stevenson, J.
    Patil, P.
    Pennell, N.
    Fidler, M. J.
    Bonomi, P.
    Qin, A.
    Niu, Z.
    Nagrath, S.
    Kalemkerian, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S863 - S863
  • [5] Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls
    Shaw, A. T.
    Yeap, B. Y.
    Solomon, B. J.
    Riely, G. J.
    Iafrate, A. J.
    Shapiro, G.
    Costa, D. B.
    Butaney, M.
    Ou, S. I.
    Maki, R. G.
    Bang, Y.
    Varella-Garcia, M.
    Salgia, R.
    Wilner, K. D.
    Kulig, K.
    Selaru, P.
    Tang, Y.
    Kwak, E. L.
    Clark, J. W.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] COST-EFFECTIVENESS ANALYSIS OF NEOADJUVANT NIVOLUMAB PLUS PLATINUM-BASED CHEMOTHERAPY (PDC) IN RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE: A SITUATION OF DOMINANCE
    Casabianca, P.
    Carette, J.
    Chouaid, C.
    Harris, M.
    Chartier, M.
    Sun, A.
    White, B.
    Leleu, H.
    Lucherini, S.
    Cotte, F. E.
    VALUE IN HEALTH, 2024, 27 (12) : S80 - S81
  • [7] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [8] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [9] CRIZOTINIB IMPROVES OVERALL SURVIVAL OF ALK-POSITIVE PATIENTS WITH ADVANCED NSCLC COMPARED WITH HISTORICAL CONTROLS
    Shaw, Alice T.
    Yeap, Beow
    Solomon, Ben
    Riely, Gregory J.
    Iafrate, A. J.
    Shapiro, Geoffrey
    Costa, Daniel B.
    Butaney, Mohit
    Ou, Sai-Hong I.
    Maki, Robert
    Bang, Yung-Jue
    Varella-Garcia, Marileila
    Salgia, Ravi
    Wilner, Keith
    Kulig, Kimary
    Selaru, Paulina
    Tang, Yiyun
    Kwak, Eunice
    Clark, Jeffrey
    Camidge, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S412 - S413
  • [10] BRIGATINIB COMPARED WITH CRIZOTINIB AND ALECTINIB IN PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASES AT DIAGNOSIS: A COST-EFFECTIVENESS ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Genov, I
    Mendes da Silva, B.
    Lanchoti Fiori, G. M.
    Villas Boas, B.
    Teixeira Chadid, T.
    Regis, C.
    VALUE IN HEALTH, 2021, 24 : S31 - S32
12345